S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis
Purpose: Several therapeutic combinations are available for the treatment of advanced gastric cancer (AGC). It is unclear which combinations are most beneficial to the patients. The purpose of this study was to compare the efficacy and safety of Tegafur/ gimeracil/ oteracil (S-1) plus oxaliplatin (S...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Computer Methods and Programs in Biomedicine Update |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666990024000181 |
| _version_ | 1797256248753651712 |
|---|---|
| author | S.M.Zeeshan Qadar Zhiyong Dong Sheikh Mohammed Shariful Islam Jianxue Wang Xiling Xu Fakhsheena Anjum Sana Shamim Bafreen Sherif Sundas Ali |
| author_facet | S.M.Zeeshan Qadar Zhiyong Dong Sheikh Mohammed Shariful Islam Jianxue Wang Xiling Xu Fakhsheena Anjum Sana Shamim Bafreen Sherif Sundas Ali |
| author_sort | S.M.Zeeshan Qadar |
| collection | DOAJ |
| description | Purpose: Several therapeutic combinations are available for the treatment of advanced gastric cancer (AGC). It is unclear which combinations are most beneficial to the patients. The purpose of this study was to compare the efficacy and safety of Tegafur/ gimeracil/ oteracil (S-1) plus oxaliplatin (S-1OX) with capecitabine plus oxaliplatin (CAPOX) in patients with AGC. Materials and Methods: Relevant randomized controlled trials were searched in MEDLINE, EMBASE, The Cochrane Library (CENTRAL), two major Chinese biomedical databases (CBM, CNKI), and registry centers until July 22, 2019, with no language restrictions. Data were extracted for overall response rate (ORR), time to progression (TTP), overall survival time (OST), and toxicity. The systematic review was performed according to the recommendations of the Cochrane collaboration. RevMan 5.3.1 was used for statistical analysis. Results: A total of 6 randomized controlled trials involving 911 patients were included. The quality of the trials was less than 3 points. All the trials demonstrated a significantly improved toxicity (hand-foot syndrome and neuropathy) in the S-1OX trials (p < 0.05). There was no statistically significant difference (p > 0.05) between S-1OX versus CAPOX in terms of ORR, OST, TTP. Any of the subgroup analyses did not exhibit heterogeneity, so the fixed-effects model be used to execute the subgroup meta-analysis. Conclusions: Both S-1OX and CAPOX showed similar efficacy for treatment of AGC. However, S1-OX appeared to present less toxicity in terms of hand-foot syndrome and neuropathy as compared to CAPOX. |
| first_indexed | 2024-04-24T22:18:44Z |
| format | Article |
| id | doaj.art-055f5f6ae8c24a65969dd9e7673095f0 |
| institution | Directory Open Access Journal |
| issn | 2666-9900 |
| language | English |
| last_indexed | 2024-04-24T22:18:44Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Computer Methods and Programs in Biomedicine Update |
| spelling | doaj.art-055f5f6ae8c24a65969dd9e7673095f02024-03-20T06:11:32ZengElsevierComputer Methods and Programs in Biomedicine Update2666-99002024-01-015100151S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysisS.M.Zeeshan Qadar0Zhiyong Dong1Sheikh Mohammed Shariful Islam2Jianxue Wang3Xiling Xu4Fakhsheena Anjum5Sana Shamim6Bafreen Sherif7Sundas Ali8National Collaborative Centre for Infectious Disease (NCCID), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, CanadaThe George Institute for Global Health, The University of Sydney, Camperdown NSW, 2050, AustraliaDeakin University, Faculty of Health, School of Exercise & Nutrition Science, AustraliaThe George Institute for Global Health, The University of Sydney, Camperdown NSW, 2050, AustraliaDepartment of Gastrointestinal Surgery, the Affiliated Hospital of Putian University, Putian, ChinaDepartment of Pharmacy Practice, Dow College of Pharmacy, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, OJHA campus, Karachi, Pakistan; Corresponding author at: Department of Pharmacy Practice, Dow College of Pharmacy, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, OJHA campus, Karachi, Pakistan.Department of Pharmaceutical Chemistry, Dow College of Pharmacy, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, OJHA campus, Karachi, PakistanInpatient Pharmacy Department I Waitemata DHB, North Shore Hospital, Shakespeare Rd, Takapuna, Auckland, New ZealandDepartment of Community Medicine, University of Lahore, PakistanPurpose: Several therapeutic combinations are available for the treatment of advanced gastric cancer (AGC). It is unclear which combinations are most beneficial to the patients. The purpose of this study was to compare the efficacy and safety of Tegafur/ gimeracil/ oteracil (S-1) plus oxaliplatin (S-1OX) with capecitabine plus oxaliplatin (CAPOX) in patients with AGC. Materials and Methods: Relevant randomized controlled trials were searched in MEDLINE, EMBASE, The Cochrane Library (CENTRAL), two major Chinese biomedical databases (CBM, CNKI), and registry centers until July 22, 2019, with no language restrictions. Data were extracted for overall response rate (ORR), time to progression (TTP), overall survival time (OST), and toxicity. The systematic review was performed according to the recommendations of the Cochrane collaboration. RevMan 5.3.1 was used for statistical analysis. Results: A total of 6 randomized controlled trials involving 911 patients were included. The quality of the trials was less than 3 points. All the trials demonstrated a significantly improved toxicity (hand-foot syndrome and neuropathy) in the S-1OX trials (p < 0.05). There was no statistically significant difference (p > 0.05) between S-1OX versus CAPOX in terms of ORR, OST, TTP. Any of the subgroup analyses did not exhibit heterogeneity, so the fixed-effects model be used to execute the subgroup meta-analysis. Conclusions: Both S-1OX and CAPOX showed similar efficacy for treatment of AGC. However, S1-OX appeared to present less toxicity in terms of hand-foot syndrome and neuropathy as compared to CAPOX.http://www.sciencedirect.com/science/article/pii/S2666990024000181Oxaliplatin (OX)Capecitabine (CAP)Adjuvant chemotherapyAdvanced gastric cancer (AGC)Meta-analysis |
| spellingShingle | S.M.Zeeshan Qadar Zhiyong Dong Sheikh Mohammed Shariful Islam Jianxue Wang Xiling Xu Fakhsheena Anjum Sana Shamim Bafreen Sherif Sundas Ali S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis Computer Methods and Programs in Biomedicine Update Oxaliplatin (OX) Capecitabine (CAP) Adjuvant chemotherapy Advanced gastric cancer (AGC) Meta-analysis |
| title | S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis |
| title_full | S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis |
| title_fullStr | S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis |
| title_full_unstemmed | S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis |
| title_short | S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis |
| title_sort | s 1 plus oxaloplatin s 1ox versus capecitabine plus oxaloplatin capox for advanced gastric cancer a systematic review and meta analysis |
| topic | Oxaliplatin (OX) Capecitabine (CAP) Adjuvant chemotherapy Advanced gastric cancer (AGC) Meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2666990024000181 |
| work_keys_str_mv | AT smzeeshanqadar s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT zhiyongdong s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT sheikhmohammedsharifulislam s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT jianxuewang s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT xilingxu s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT fakhsheenaanjum s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT sanashamim s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT bafreensherif s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis AT sundasali s1plusoxaloplatins1oxversuscapecitabineplusoxaloplatincapoxforadvancedgastriccancerasystematicreviewandmetaanalysis |